Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bayer, CHOP Partner to Develop Oral NRT | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Bayer, CHOP Partner to Develop Oral NRT

Bayer is investing $5 million in the joint research over three years, with the option of continuing the collaboration

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bayer has entered into a three-year collaboration agreement with Children’s Hospital of Philadelphia (CHOP) for the discovery and development of small molecules (SMOLs) for a first-in-class oral non-replacement therapy (NRT) for the treatment of hemophilia A and B. The partnership will combine CHOP’s expertise in hemophilia and coagulation and Bayer’s research capabilities.
 
Hemophilia is a genetic bleeding disorder in which one of the clotting proteins needed to form blood clots in the body is missing or defective. The main treatment for hemophilia is called replacement therapy and is often administered multiple times a week to help replace the clotting factor that’s missing or low. An orally available SMOL for the treatment of hemophilia would be a new modality in the market, and has the potential to remove the burden of frequent injections. 
 
Under the agreement, Bayer is investing $5 million in the joint research over three years, with the option of continuing the collaboration. Bayer will have an option to exclusively license the collaboration results.
 
“Bayer is committed to investing and researching the next-generation of groundbreaking therapies. Small molecule therapies could help thousands of people with hemophilia A and B and we are looking forward to combining our strength in hemophilia research with Children’s Hospital of Philadelphia, which is a leading institution in basic and clinical research in the field of hemophilia” said Dr. Joerg Moeller, member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of Research and Development. “This innovative approach is unprecedented in pharmaceutical history and would leverage significant opportunities for continued innovation in hemophilia”.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics